PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Meta Expands AI Training With Employee Activity Tracking Tools 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
NEWTON, Mass., March 07, 2016 -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and full year 2015 financial results and provide a company update on Monday, March 14, 2016. Karyopharm’s management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2016 to discuss the financial results and recent business developments.
To access the conference call, please dial (855) 437-4406 (local) or (484) 756-4292 (international) at least five minutes prior to the start time and refer to conference ID 59463471. A live audio webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, investors.karyopharm.com/events.cfm. An archived webcast will be available on the Company's website approximately two hours after the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of inflammation, autoimmune disease, neurological disorders, certain viruses and wound-healing. Karyopharm was founded by Dr. Sharon Shacham and is located in Newton, Massachusetts. For more information, please visit www.karyopharm.com.
Contact: Justin Renz (617) 658-0574 [email protected] Gina Nugent (617) 460-3579 [email protected]
